CA2575497A1 - Composition de stearate amelioree et procede - Google Patents
Composition de stearate amelioree et procede Download PDFInfo
- Publication number
- CA2575497A1 CA2575497A1 CA002575497A CA2575497A CA2575497A1 CA 2575497 A1 CA2575497 A1 CA 2575497A1 CA 002575497 A CA002575497 A CA 002575497A CA 2575497 A CA2575497 A CA 2575497A CA 2575497 A1 CA2575497 A1 CA 2575497A1
- Authority
- CA
- Canada
- Prior art keywords
- earth metal
- alkaline earth
- composition
- stearate
- dihydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims description 39
- 238000004519 manufacturing process Methods 0.000 title description 16
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims abstract description 49
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract description 47
- -1 alkaline earth metal stearate Chemical class 0.000 claims abstract description 44
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 43
- 239000000194 fatty acid Substances 0.000 claims abstract description 43
- 229930195729 fatty acid Natural products 0.000 claims abstract description 43
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 43
- 235000021355 Stearic acid Nutrition 0.000 claims abstract description 34
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract description 31
- 235000021314 Palmitic acid Nutrition 0.000 claims abstract description 27
- 239000008117 stearic acid Substances 0.000 claims abstract description 27
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229910052751 metal Inorganic materials 0.000 claims abstract description 5
- 239000002184 metal Substances 0.000 claims abstract description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 94
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 48
- 235000019359 magnesium stearate Nutrition 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 26
- 239000002002 slurry Substances 0.000 claims description 24
- 239000007864 aqueous solution Substances 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 13
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 13
- CYPFMVTZEDNCQV-UHFFFAOYSA-L magnesium;octadecanoate;dihydrate Chemical compound O.O.[Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CYPFMVTZEDNCQV-UHFFFAOYSA-L 0.000 claims description 10
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- 239000011777 magnesium Substances 0.000 claims description 7
- 239000002244 precipitate Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000000926 separation method Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 3
- 229910017604 nitric acid Inorganic materials 0.000 claims description 3
- 150000007524 organic acids Chemical class 0.000 claims description 3
- OUOPFMMIKLEKSS-UHFFFAOYSA-N octadecanoic acid;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(O)=O OUOPFMMIKLEKSS-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 150000004683 dihydrates Chemical group 0.000 abstract description 45
- 239000000344 soap Substances 0.000 abstract description 13
- 229910001854 alkali hydroxide Inorganic materials 0.000 abstract description 4
- 150000008044 alkali metal hydroxides Chemical class 0.000 abstract description 4
- 239000012266 salt solution Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 23
- 238000001035 drying Methods 0.000 description 15
- 239000008149 soap solution Substances 0.000 description 13
- 150000004682 monohydrates Chemical class 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000001556 precipitation Methods 0.000 description 9
- 239000000314 lubricant Substances 0.000 description 8
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000036571 hydration Effects 0.000 description 7
- 238000006703 hydration reaction Methods 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 229940063002 magnesium palmitate Drugs 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010979 pH adjustment Methods 0.000 description 3
- 150000002943 palmitic acids Chemical class 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000002411 thermogravimetry Methods 0.000 description 3
- 150000004684 trihydrates Chemical class 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- JLFVIEQMRKMAIT-UHFFFAOYSA-N ac1l9mnz Chemical compound O.O.O JLFVIEQMRKMAIT-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 2
- ABSWXCXMXIZDSN-UHFFFAOYSA-L magnesium;hexadecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O ABSWXCXMXIZDSN-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003637 basic solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 229940064790 dilantin Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- NIBNQSROBWMZTK-UHFFFAOYSA-L magnesium hexadecanoate dihydrate Chemical compound O.O.[Mg++].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCC([O-])=O NIBNQSROBWMZTK-UHFFFAOYSA-L 0.000 description 1
- RJXMFWOTBFWULV-UHFFFAOYSA-L magnesium hexadecanoate octadecanoate dihydrate Chemical compound O.O.[Mg++].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O RJXMFWOTBFWULV-UHFFFAOYSA-L 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- MPBQUSJTYPZEIZ-UHFFFAOYSA-L magnesium;hexadecanoate;octadecanoate Chemical compound [Mg+2].CCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O MPBQUSJTYPZEIZ-UHFFFAOYSA-L 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000005555 metalworking Methods 0.000 description 1
- 229960001165 modafinil Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000008019 pharmaceutical lubricant Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910009112 xH2O Inorganic materials 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Lubricants (AREA)
Abstract
L'invention concerne une composition de stéarate de métal alcalino-terreux améliorée, élaborée par réaction entre une composante d'acide gras à acide stéarique et acide palmitique, et un hydoxyde alcalin, pour la formation de savon alcalin. On ajoute ensuite une solution de sel métallique aqueuse au savon, et le pH est réglé à moins d'environ 8 pour la formation du stéarate considéré, lequel offre une quantité sensiblement pure de forme dihydrate du stéarate.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| USPCT/US2004/024485 | 2004-07-28 | ||
| PCT/US2004/024485 WO2005011641A2 (fr) | 2003-07-28 | 2004-07-28 | Composition de stearate amelioree et procede |
| PCT/US2005/021707 WO2006023035A2 (fr) | 2004-07-28 | 2005-06-16 | Composition de stearate amelioree et procede |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2575497A1 true CA2575497A1 (fr) | 2006-03-02 |
Family
ID=35840715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002575497A Abandoned CA2575497A1 (fr) | 2004-07-28 | 2005-06-16 | Composition de stearate amelioree et procede |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1781259A2 (fr) |
| JP (1) | JP2008509092A (fr) |
| CN (1) | CN1988890A (fr) |
| AU (1) | AU2005277992A1 (fr) |
| CA (1) | CA2575497A1 (fr) |
| MX (1) | MXPA06014216A (fr) |
| WO (1) | WO2006023035A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102372620B (zh) * | 2010-08-17 | 2015-11-25 | 安徽山河药用辅料股份有限公司 | 硬脂酸镁提高其比容和白度的制备方法 |
| JP7110756B2 (ja) * | 2018-06-22 | 2022-08-02 | 日油株式会社 | 脂肪酸マグネシウム塩組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5277832A (en) * | 1991-09-12 | 1994-01-11 | Freiborne Industries, Inc. | Recovery of reactive soap lubricants |
| JP2003504415A (ja) * | 1999-07-20 | 2003-02-04 | メルク エンド カムパニー インコーポレーテッド | 持続放出性薬物分散剤輸送装置 |
| AU2002322424A1 (en) * | 2001-07-31 | 2003-02-17 | Royer Biomedical, Inc. | Novel methods and formulations for administration of active agents |
-
2005
- 2005-06-16 CN CNA2005800253184A patent/CN1988890A/zh active Pending
- 2005-06-16 EP EP05764429A patent/EP1781259A2/fr not_active Withdrawn
- 2005-06-16 AU AU2005277992A patent/AU2005277992A1/en not_active Abandoned
- 2005-06-16 WO PCT/US2005/021707 patent/WO2006023035A2/fr not_active Ceased
- 2005-06-16 MX MXPA06014216A patent/MXPA06014216A/es active IP Right Grant
- 2005-06-16 CA CA002575497A patent/CA2575497A1/fr not_active Abandoned
- 2005-06-16 JP JP2007523564A patent/JP2008509092A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1781259A2 (fr) | 2007-05-09 |
| MXPA06014216A (es) | 2007-03-12 |
| WO2006023035A3 (fr) | 2006-06-15 |
| CN1988890A (zh) | 2007-06-27 |
| JP2008509092A (ja) | 2008-03-27 |
| AU2005277992A1 (en) | 2006-03-02 |
| WO2006023035A2 (fr) | 2006-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7280318B2 (ja) | 炭酸ランタン水酸化物、ランタンオキシカルボネートならびにその製造および使用方法 | |
| US7385068B2 (en) | Stearate composition and method | |
| EP2462062B1 (fr) | Hydroxydes doubles lamellaires de magnesium et de fer, leur production et leur utilisation pour le traitement de hyperphosphataemia | |
| AU2006226293B2 (en) | Solubilized ibuprofen | |
| EP0380829B1 (fr) | Citrate de magnésium et de potassium | |
| CN108794552B (zh) | 一种琥乙红霉素球形晶体及其制备方法 | |
| JP5926195B2 (ja) | 直接圧縮可能な水酸化炭酸マグネシウム | |
| AU2005277992A1 (en) | Improved stearate composition and method of production thereof | |
| PL175923B1 (pl) | Krystaliczna postać wodorowęglanu potasu i sposób wytwarzania krystalicznej postaci wodorowęglanu potasu | |
| US4895980A (en) | Method of manufacturing magnesium potassium citrate | |
| JP2009051715A (ja) | 非晶質球状珪酸アルミニウム、その製造方法および該珪酸アルミニウムを用いた製剤。 | |
| CN106810587A (zh) | 制备无定型奥贝胆酸的方法 | |
| JP5093907B2 (ja) | 無水第二リン酸カルシウム粒子およびその製造方法 | |
| WO2005067936A2 (fr) | Procedes de fabrication de sildenafil base et de son sel citrate | |
| JPS6254116B2 (fr) | ||
| NZ519550A (en) | Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith | |
| CA1326040C (fr) | Citrate de magnesium-potassium | |
| EP1722772A1 (fr) | Supplement dietetique a base de citrate de magnesium et de potassium stoechiometriquement specifique | |
| JP3898662B2 (ja) | 結晶性エチドロン酸2ナトリウム水和物 | |
| JP2003522749A (ja) | ムチン酸とのl−カルニチンおよびアルカノイルl−カルニチンの塩の調製法 | |
| KR20000073242A (ko) | 의약용 스테아린산 마그네슘의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued | ||
| FZDE | Discontinued |
Effective date: 20110616 |